Evaxion Announces Upcoming Business Update
Evaxion A/S (NASDAQ: EVAX), a pioneering clinical-stage TechBio company, focuses on developing AI-Immunology™ powered vaccines. Recently, the company shared exciting news about its upcoming business update and the first-quarter financial results for 2025. This event is set to take place on a Tuesday and promises to provide valuable insights into Evaxion’s activities and financial performance.
Conference Call Details
On the day of the business update, Evaxion's Executive Management will host a conference call at 14:30 CET/08:30 EST. Attendees can expect a comprehensive presentation covering the company's latest developments, results, and a chance to engage in Q&A. This conference call marks an essential component of Evaxion's commitment to transparency and stakeholder communication.
How to Join the Conference Call
For those wishing to participate in the conference call, pre-registration is encouraged. Interested individuals can easily secure their spot by registering to receive dial-in numbers and a unique PIN code. This allows for seamless access to the event, which opens 15 minutes prior to the start time.
Webcast Participation
Evaxion will also provide a webcast option for those who prefer to join online. A link will be available for viewers to watch the presentation live and catch any subsequent discussions. Following the event, a recording of the webcast will be accessible on the company's website, ensuring that those unable to attend can stay informed.
About Evaxion and Its Innovative Approach
As a TechBio leader, Evaxion A/S stands at the forefront of vaccine development by utilizing its proprietary AI platform, AI-Immunology™. This advanced technology enables the company to harness artificial intelligence in decoding the human immune system. Through this approach, Evaxion aims to develop innovative immunotherapies that target cancer, bacterial diseases, and viral infections.
Revolutionizing Vaccine Development
Evaxion’s dedication to transforming patient care is evident in its robust pipeline. The company has made significant strides in personalized oncology vaccines, designed to be tailored to individual patient needs. Additionally, its preclinical pipeline addresses critical infectious diseases, highlighting the company's commitment to tackling high-unmet medical needs.
Contact Information
For inquiries, individuals can reach out to Evaxion's Vice President of Investor Relations & Communication, Mads Kronborg, at +45 53 54 82 96 or via email at mak@evaxion.ai. This open line of communication further emphasizes Evaxion’s mission of transparency and engagement with stakeholders.
Frequently Asked Questions
What is the purpose of Evaxion's upcoming business update?
The business update will provide insights into the company's latest developments and first-quarter financial results for 2025.
How can I participate in the conference call?
Interested participants should register in advance to receive dial-in details and participate in the Q&A session.
Will the conference call be available online?
Yes, a webcast will be available for those who prefer to join online, and a recording will be posted on Evaxion's website afterward.
What technologies does Evaxion focus on?
Evaxion specializes in AI-Immunology™, which leverages artificial intelligence to develop innovative vaccines targeting cancer and infectious diseases.
Who can I contact for more information about Evaxion?
You can contact Mads Kronborg, Vice President of Investor Relations & Communication, at +45 53 54 82 96 or via email.